COVID-19, severe asthma, and biologic
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 38(2021), 4 vom: 23. Apr., Seite 423-426 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
COVID-19, asthme sévère et biothérapies |
|---|
| Beteiligte Personen: |
Underner, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACE2 protein, human |
|---|
| Anmerkungen: |
Date Completed 19.05.2021 Date Revised 19.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2021.03.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32327336X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32327336X | ||
| 003 | DE-627 | ||
| 005 | 20231225183829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2021.03.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM32327336X | ||
| 035 | |a (NLM)33771438 | ||
| 035 | |a (PII)S0761-8425(21)00162-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Underner, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19, severe asthma, and biologic |
| 246 | 3 | 3 | |a COVID-19, asthme sévère et biothérapies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2021 | ||
| 500 | |a Date Revised 19.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Asthme sévère | |
| 650 | 4 | |a Biologic | |
| 650 | 4 | |a Biothérapies | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Severe asthma | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Taillé, C |e verfasserin |4 aut | |
| 700 | 1 | |a Peiffer, G |e verfasserin |4 aut | |
| 700 | 1 | |a Perriot, J |e verfasserin |4 aut | |
| 700 | 1 | |a Jaafari, N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 38(2021), 4 vom: 23. Apr., Seite 423-426 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2021 |g number:4 |g day:23 |g month:04 |g pages:423-426 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2021.03.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2021 |e 4 |b 23 |c 04 |h 423-426 | ||